Compare Genuine Parts Company (GPC) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Tango Therapeutics Inc. — how do they compare? Genuine Parts Company trades at $131.49 (market cap $18.02B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Genuine Parts Company is far larger — about 4.8× Tango Therapeutics Inc.'s market cap, and Genuine Parts Company pays a 3.25% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and Tango Therapeutics Inc. for 0 Days on average.
| GPC | TNGX | |
|---|---|---|
Market Cap | $18.02B | $3.75B |
Volume | 744,000 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $32.90 |
52-Week Low | $92.47 | $7.50 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | $24.11B | $2.77B |
Dividend Yield | 3.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $131.63, up 1.55% today, with a bullish technical signal and analyst consensus price target of $145.75. Recent earnings show mixed results, with Q1 and Q2 2026 beats but a Q4 2025 miss, while net income margin remains thin at 0.13%. The company is progressing with its planned separation into automotive and industrial businesses by Q1 2027, a key strategic move highlighted in recent news.
The outlook is cautiously optimistic, supported by the corporate split catalyst and steady revenue growth, but risks include low profitability margins and rising debt levels. Analyst sentiment leans positive with 10 buy ratings, though valuation metrics like a high P/E of 522.84 warrant attention for potential investors.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
